Brief: Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration
23/06/2025 21:40
June 23 (Reuters) - Terns Pharmaceuticals Inc TERN.O: TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS TERNS PHARMACEUTICALS INC - TERN-601 WELL-TOLERATED WITH RAPID DOSE TITRATION TERNS PHARMACEUTICALS- PHASE 2 FALCON CLINICAL TRIAL OF TERN-601 COMPLETED ENROLLMENT; 12-WEEK DATA EXPECTED IN 4Q 2025 Source text: ID:nGNX8X0HP Further company coverage: TERN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.